675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC)A. Dimitrios Colevas, Douglas Adkins, John Park et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.A. Dimitrios Colevas, Douglas Adkins, José Dinis et al.|Journal of Clinical Oncology|2023Cited by 0